Canaccord Genuity Maintains Buy on Lucid Diagnostics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Lucid Diagnostics (NASDAQ:LUCD) with a $3 price target.
August 13, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Lucid Diagnostics with a $3 price target.
The reaffirmation of a Buy rating and a specific price target of $3 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100